We described progressive alterations of blood NK cells in melanoma patients according to clinical stages (stage I to IV) with a significant decrease of NKp46 expression on blood NK cells from stage IV metastatic melanoma patients and an alteration of their functional abilities [10]. The gene discussed is NCR1; the disease is melanoma.